Changes in Fasting Glucose Levels Were Similar Between INVEGA HAFYERA™ and INVEGA TRINZA®

Change in Fasting Glucose From the Randomized, Double-blind Phase1

Chart depicting changes in fasting glucose from the double-blind phase

Table reflects subjects with paired fasting data (baseline and any post-baseline assessment).

Using the conversion factor (1 mg/dL=0.05551 mmol/L), the ADA-specified limits are as follows:

Normal: <100 mg/dL (<5.551 mmol/L)

Impaired: ≥100 mg/dL (≥5.551 mmol/L) to <126 mg/dL (<6.994 mmol/L)

High: ≥126 mg/dL (≥6.994 mmol/L)

126 mg/dL=6.994 mmol/L; 140 mg/dL=7.771 mmol/L; 200 mg/dL=11.102 mmol/L; 300 mg/dL=16.653 mmol/L

ADA=American Diabetes Association.

Hyperglycemia and diabetes mellitus
  • Monitor for symptoms of hyperglycemia, including polydipsia, polyuria, polyphagia, and weakness
  • Monitor glucose regularly in patients with diabetes or at risk for diabetes

Changes in Fasting Lipids Were Similar Between INVEGA HAFYERA™ and INVEGA TRINZA®

Shifts in Fasting Lipids in the Double-blind Phase From the Randomized, Active-controlled Study1

Chart depicting changes in fasting lipids from the double-blind phase

For each fasting parameter, patients with both baseline (DB) record and any post-baseline (DB) record during the double-blind phase are included in the denominator.

DB=double-blind phase.

  • Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

REFERENCE: 1. INVEGA HAFYERA™ [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; August 2021.